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An estimated 760,000 cardiac surgical procedures wereperformed in the United States in 1997, including
607,000 coronary bypass operations.1 In Canada there
were over 18,000 coronary artery bypass graft (CABG)
procedures in 1995-1996.2 In Europe 153,670 CABG
procedures and 56,574 valve replacements were done in
1993.3 Infectious complications are a major source of
morbidity and mortality postoperatively. The incidence of
infection at the surgical sites, chest and leg, ranges from
less than 1% to greater than 10%4-6 and increases accord-
ing to the severity of underlying disease.7 Infection ranges
from superficial involvement of the wound to deeper soft
tissue infection, sternal osteomyelitis, and mediastinitis,
requiring surgical drainage and debridement, as well as
antimicrobial therapy.
Objective: Cephalosporins, especially cefazolin, are widely used in the pre-
vention of postoperative wound infections after cardiac operations. As more
and more Staphylococcus aureus and Staphylococcus epidermidis strains are
becoming resistant to cephalosporins and other antibiotics, alternative
agents, such as glycopeptides, are often used as prophylaxis. We performed
a multicenter double-blind randomized controlled trial comparing
teicoplanin, a glycopeptide antibiotic, with cefazolin.
Methods: A total of 3027 adult patients undergoing elective coronary artery
bypass grafting, valve operations, or both were randomized to a single dose
of teicoplanin (15 mg/kg) or a 2-day course of cefazolin (2 g initial dose, fol-
lowed by 1 g every 8 hours for 6 more doses). Patients were followed up for
a total of 6 months postoperatively. The primary objective was to compare,
between groups, the incidence of surgical infections up to 30 days postoper-
atively. Secondary objectives were incidence of other infections, other com-
plications, and death.
Results: A total of 3027 patients were randomized to receive either
teicoplanin (n = 1518) or cefazolin (n = 1509). Thirty days postoperatively,
there was a trend to more deep sternotomy wound infections in the
teicoplanin group (31 vs 18, P = .087), which became significant by 6
months (36 vs 19, P = .032). One hundred percent of the gram-positive
strains infecting patients were susceptible to teicoplanin, whereas 8.3% were
resistant to cefazolin. Pneumonia and urinary tract infections were more
common in the teicoplanin group. Deep wound infections of the leg were
more common in the cefazolin group.
Conclusions: Cefazolin was more effective prophylaxis than teicoplanin
against postoperative wound infections after elective cardiac operations.
Infection rates were low with either treatment.  (J Thorac Cardiovasc Surg
2000;120:1120-30)
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Ten to thirty percent of cardiac surgical patients with
deep wound infections die during their hospitalization.
The duration of hospital stay is markedly prolonged by
a mean of 12 to 16 days.8,9 The attributable cost is enor-
mous, estimated at approximately $37,000 in one
American study or an increase of 180% over that of
uninfected patients.4 Patients undergoing cardiac
surgery are also at risk for the development of infec-
tions unrelated to the surgical site, such as pneumonia,
urinary tract infection, and bacteremia, with the latter
often related to line sepsis.
The most common pathogens associated with these
infections are Staphylococcus epidermidis, Staphylo-
coccus aureus, and gram-negative bacilli, such as
Enterobacter species.10-12 Antibiotic prophylaxis is
widely used to reduce the incidence of postoperative
infection. Limited placebo-controlled data suggest that
this prophylactic use of antimicrobials is efficacious in
preventing infection at the surgical site.13 In North
America the antibiotics of choice are cephalosporins.14
Cefazolin, cefamandole, and cefuroxime have been
found to be safe and effective.15-19 There is no consis-
tent advantage of one over the others. Vancomycin, the
glycopeptide available in the United States and Canada,
is widely used in patients with β-lactam allergy.
A high incidence of β-lactam–resistant S epidermidis
and a rising tide of methicillin-resistant S aureus
(MRSA) susceptible to vancomycin have raised interest
in glycopeptides as prophylaxis in cardiac operations.
Doubts have been cast about the efficacy of a
cephalosporin, cefazolin, in preventing infection
caused by S aureus.20 Furthermore, there has been con-
cern about the selection or induction of resistance in
organisms, such as coagulase-negative staphylococci
and Enterobacter species, in cephalosporin recipients.
Two rigorous comparative studies have assessed the
use of glycopeptides as prophylactic agents in cardiac
operations. Wilson and colleagues21 compared
teicoplanin with the combination of flucloxacillin and
tobramycin in a total of 517 patients. Teicoplanin was
less effective than the combination.
Maki and associates22 compared vancomycin with
cefamandole and cefazolin in a population of 321
patients undergoing cardiovascular (mostly cardiac)
operations. In that study vancomycin was more effec-
tive than the cephalosporins. However, hypotension
was a significant complication of vancomycin, occur-
ring in 8% of patients.
The ESPRIT study group sought to compare
teicoplanin with cefazolin for cardiac operation pro-
phylaxis. The pharmacokinetic properties of
teicoplanin lend themselves to surgical prophylaxis.
The drug has a long half-life, 130 to 166 hours with a
3-compartment model, allowing the use of a single
high dose.23-25 The antibiotic is concentrated in cardiac
tissue.26 Clearance of teicoplanin during cardiopul-
monary bypass is similar to that found in nonsurgical
patients.27 Unlike vancomycin, teicoplanin does not
result in histamine release, which may cause rash and
hypotension, and the drug can be given by means of
rapid infusion without toxicity.28 It is less nephrotoxic
than vancomycin.29
Methods
Design. This was a randomized controlled double-blind
study done at 13 university-affiliated cardiac surgical centers
across Canada. At each site, only the pharmacist was unblind-
ed, and he or she was responsible for the distribution of
drugs. The study nurses, surgeons, anesthetists, and physi-
cians were unaware of each patient’s prophylaxis regimen
assignment. Randomization was done within 3 strata: CABG,
valve replacement-repair, or both. The randomization was
generated for each site by an independent statistician using a
computer-generated list.
Patients. Adult (≥18 years of age) patients undergoing
elective CABG, valve operations (replacement or repair), or
both were eligible for the trial. An elective operation was
defined as a procedure planned at least 24 hours ahead. A
signed written informed consent was obtained from each
patient. Blood counts, serum creatinine levels, and urine cul-
tures were procured. At each center, there was approval by
the local research ethics board.
Exclusion criteria included the following: patients who
were pregnant and those who had previously undergone ster-
notomy procedures; patients with severe concomitant dis-
eases, such as the immunocompromised; patients who were
morbidly obese; and individuals with osteotomies. Medically
unstable patients and those with ventricular assist devices
and/or requiring intra-aortic balloon pumps, transplant, or
total artificial hearts were not enrolled. Patients who had
received systemic antibiotics in the preoperative week and
those allergic to glycopeptides, penicillins, or cephalosporins
were not eligible. Active bacterial infections precluded entry
into the study, but asymptomatic bacteriuria was allowed.
Patients with serum creatinine levels of 250 µmol/L or more
(2.8 mg/dL) or neutropenia of 1000 cells/mm3 or less were
excluded. Use of an investigational drug or device in the 30
days before the operation was not allowed nor was prior par-
ticipation in a trial with teicoplanin. Patients of mental capac-
ity so limited as to preclude informed consent were not
enrolled.
An outbreak of MRSA occurred at one study center during
the course of the study. Enrollment was interrupted at that site
for the duration of the outbreak and then resumed.
Drug administration. Teicoplanin or cefazolin was pack-
aged in 50-mL bags of normal saline solution to be infused
over 15 minutes. Teicoplanin was given as a single preopera-
tive dose of 15 mg/kg within 30 minutes of initial skin inci-
sion at the donor site or sternum, followed by placebo (nor-
mal saline solution, 50 mL) every 8 hours for 6 more doses.
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Cefazolin was administered as a 2-g preoperative dose, fol-
lowed by 1 g every 8 hours for 6 more doses. The preopera-
tive dose of study drug was covered with an opaque contain-
er to prevent identification of infusate in the bag, with
teicoplanin solution being yellow-brown in color.
Assessment. Patients were seen by the research team
before their operations, the first postoperative day, and at
least 3 times weekly until discharge.
There was a follow-up visit or telephone contact of all
patients at 30 days and 6 months postoperatively. All patient
assessments and interpretations of patient outcomes were
done before the data were unblinded.
Date of onset of infection was defined as the day of first
physician visit or culture for the infectious illness or the date
of readmission for infection, whichever came first.
Definitions were made before the onset of the study for
important infectious syndromes relevant to the study:
1. Superficial thoracic wound infection: cellulitis, with
systemic signs of infection, and/or purulent wound dis-
charge (spontaneous or by aspiration)
2. Deep thoracic infections
A. Deep wound infection: wound infection requiring
drainage and/or debridement
B. Sternal osteomyelitis: a deep sternal wound infec-
tion with evidence of bony infection (gross appear-
ance, histopathology, and/or culture of bone) at
operation for infection
C. Mediastinitis: a deep sternal wound infection with
evidence of mediastinal involvement (gross appear-
ance, histopathology, and/or culture) documented
at operation for infection
D. Endocarditis: at least 2 of the following: (1) com-
patible clinical illness with evidence of cardiac
involvement or no evidence of extracardiac source;
(2) at least 2 positive blood cultures for the same
organism; and (3) microbiologic or histopathologic
evidence of valvular infection at reoperation or at
autopsy
E. Pericarditis: infection of the pericardium defined at
the operation and/or by aspiration
3. Donor site infections
A. Superficial donor site infection: cellulitis, with sys-
temic signs of infection, and/or purulent wound
discharge (spontaneous or by aspiration)
B. Deep donor site infection: wound infection requir-
ing drainage and/or debridement
4. Bacteremia: at least one positive blood culture for a
gram-negative microorganism or 2 positive blood cul-
tures for the same gram-positive bacterium
5. Respiratory tract infections
A. Pneumonia. Definite: presence of a consistent syn-
drome (eg, fever or cough), infiltrate on chest x-ray
film, and positive cultures of respiratory secretions
(expectorated sputum showing less than 10 squa-
mous epithelial cells per low-power field and more
than 25 polymorphonuclear leukocytes per high-
power field). Probable: purulent sputum (>25 poly-
morphonuclear neutrophils per high-power field)
plus an atypical infiltrate on chest x-ray film.
Possible: atypical infiltrate
B. Tracheobronchitis: cough and purulent sputum in
the absence of an infiltrate on chest x-ray film
6. Urinary tract infections: greater than 105 colony-
forming units per milliliter in a cleanly voided speci-
men. In the presence of asymptomatic bacteriuria
caused by the same organism preoperatively, the uri-
nary tract infection was considered not attributable to
the intervention and not counted
Definitions for other infections were based on those pro-
posed by Pirsch and Maki.30
Objectives. The primary objective of the study was to
compare the efficacy of single-dose teicoplanin with multi-
ple-dose cefazolin in the prophylaxis of surgical infections 1
month after elective cardiac operations.
Secondary objectives were to compare both drugs in the
prevention of surgical infections at the time of hospital dis-
charge and 6 months postoperatively; to compare both drugs
in the prevention of nonsurgical infections, noninfectious
complications, and mortality at discharge, 1 month, and 6
months after the operation; to compare the microorganisms
responsible for infections after operations; and to compare
the safety of the 2 drugs.
Sample size estimation. The sample size was based on a
surgical infection rate of approximately 2% among partici-
pating centers on the basis of informal surveys, which is con-
sistent with literature reports in the 1% to 10% range. With a
significance level of 5% and a power of 80% and using a 2-
sample χ2 test, this required 1239 patients per arm.
Safety monitoring committee. Interim analysis was per-
formed by an independent safety monitoring committee, con-
sisting of a methodologist, a statistician, and a pediatric
infectious disease specialist. Three analyses were performed
(ie, one each after 600, 1200, and 1800 patients). The criteri-
on for statistical significance was modified because of the 3
interim analyses. 
Results
Of 12,198 individuals screened for inclusion into the
study, 8973 were ineligible, 3225 were eligible, and
178 withdrew before their operation or their operation
was canceled. Twenty others withdrew for other rea-
sons. A total of 3027 were randomized: 1518 received
teicoplanin, and 1509 received cefazolin.
Patient demographics are outlined in Table I. There
was no significant difference between groups in sex,
age, race, weight, severity of heart disease, or duration
of preoperative stay. The number of patients with dia-
betes was similar in both arms of the study.
A similar proportion in either group underwent
CABG only, a valve operation only, or a combined pro-
cedure.
Perioperative data are outlined in Table II. Mean pre-
operative stay in both groups was 1 week. Drugs were
administered a mean of 42 minutes before incision in
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Table I.  Patient demographics
Parameters Teicoplanin (n = 1518) Cefazolin (n = 1509) P value
Male sex, n (%) 1214 (79.9) 1206 (9.9) NS
Female sex, n (%) 304 (20.1) 303 (20.1) NS
Age, y (mean ± SD) 61.6 ± 10.2 61.4 ± 10.2 NS
Weight, kg (mean ± SD) 78.0 ± 13.9 78.9 ± 14.6 NS
Coronary artery disease, n (%) 1339 (88.2) 1313 (87.4) NS
Angina pectoris, n (%) 1335 (87.9) 1307 (86.6) NS
Class III or IV, n (%) 922 (60.7) 931 (61.7) NS
Prior myocardial infarction, n (%) 718 (47.3) 716 (47.4) NS
Valvular heart disease, n (%) 334 (22.0) 334 (22.1) NS
Ejection fraction (mean ± SD) 55.6 ± 14.5 55.0 ± 14.3 NS
Congestive heart failure, n (%) 270 (17.8) 290 (19.1) NS
Race
White, n (%) 1460 (96.2) 1449 (96.0) NS
Other, n (%) 57 (3.8) 59 (4.0) NS
Diabetes, n (%) 287 (18.9) 300 (19.9) NS
Type of operation
CABG, n (%) 1240 (81.7) 1227 (81.3) NS
Valve repair-replacement, n (%) 189 (12.5) 198 (13.1) NS
CABG and valve repair-replacement, n (%) 89 (5.9) 84 (5.6) NS
NS, Not significant.
Table II. Perioperative patient data
Parameters Teicoplanin Cefazolin
Duration of preoperative stay, d (mean ± SD) 7.4 ± 11.6 7.3 ± 11.5
Drug exposure before incision, min (mean ± SD) 42.0 ± 18 42.0 ± 18
Time in operating room, h (mean ± SD) 4.4 ± 1.0 4.4 ± 1.0
Duration of operation, h (mean ± SD) 3.9 ± 1.0 3.9 ± 1.1
Time on bypass, h (mean ± SD) 1.5 ± 0.6 1.5 ± 0.6
Estimated blood loss, mL (mean ± SD) 786.9 ± 592.9 752.9 ± 483.3
Intra-aortic balloon pump required, n (%) 31.0 (2.0) 21.0 (1.4)*
Providone skin preparation, n (%) 850.0 (56.2) 848.0 (56.4)
Chlorexidine skin preparation, n (%) 567.0 (37.5) 549.0 (36.5)
Operative site irrigation, n (%) 351.0 (23.6) 357 (24.3)
*Not significant.
Table III. Cumulative number of infections at the surgical site
Cumulative 
number of 
Teicoplanin Cefazolin P value Teicoplanin Cefazolin P value Teicoplanin Cefazolin P value patients
Superficial sternal wound 28 25 NS 71 44 .015 80 50 .011 130
Deep thoracic infections*
Total patients 24 14 NS 31 18 NS 36 19 .032 55
Deep wound 18 12 NS 23 13 NS 24 14 NS 38
Sternal osteomyelitis 6 0 .042† 6 0 .042† 7 0 .024 7
Mediastinitis 3 2 NS 4 4 NS 4 4 NS 8
Endocarditis 0 0 NS 1 0 NS 4 0 NS 4
Pericarditis 0 1 NS 0 1 NS 0 1 NS 1
NS, Not significant.
*This category includes deep wound sternal osteomyelitis, mediastinitis, endocarditis, and pericarditis. One patient may have more than one deep thoracic infection.
†Not significant because P value required for significance was established at .0412.
Hospital discharge 30 days postoperatively 6 months postoperatively
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both groups. Duration of operations (3.9 hours) and
time on cardiopulmonary bypass (1.5 hours) were the
same in both arms. There was similar blood loss. An
intra-aortic balloon pump was required in 2.0% of the
teicoplanin group and 1.4% of the cefazolin group.
Skin antisepsis was similar in both groups, with anti-
septic agents being predominantly povidone-iodine and
chlorhexidine. Fewer than a quarter of the wounds in
either group were irrigated. Superficial sternal wound
infection rates were identical at the time of hospital dis-
charge but rose over the first postoperative month to 71
(4.7%) in the teicoplanin arm and 44 (3.0%) in the
cefazolin arm (P = .015). At 6 months, the cumulative
number of infections was 80 and 50, respectively 
(P = .011; Table III).
A total of 55 deep thoracic infections were docu-
mented over the 6-month period of observation: 36 in
the teicoplanin group and 19 in the cefazolin group 
(P = .032). After 30 days, the difference between rates
(31 [2.1%] vs 18 [1.2%], respectively) was not statisti-
cally significant (P = .087). Throughout the study, ster-
nal osteomyelitis was noted exclusively in the
teicoplanin arm (at 6 months of observation, 7 [0.5%]
vs 0, P = .024). There were more deep wound infec-
tions and more cases of endocarditis in the teicoplanin
group. Rates of mediastinitis and pericarditis were sim-
ilar in the 2 groups.
The proportion of patients with superficial infections
of the donor site in the leg was similar in both groups
(Table IV). There was a trend to more deep leg infec-
tions in the cefazolin group (9 [0.7%] vs 4 [0.3%] after
1 month and 13 [1.1%] vs 4 [0.3%] after 6 months; 
P = .047). There was more pneumonia with
teicoplanin. There was significantly more tracheobron-
chitis with teicoplanin at all time intervals.
Postoperative urinary tract infection was 4 times more
common in the teicoplanin group.
Deep wound infections were found more commonly
in men, in diabetic patients, in elderly patients, and in
obese patients (Table V). Infections were also more
common in patients with longer preoperative stays and
longer surgical procedures. In both groups significant
differences were observed only in patients with dia-
betes and in patients whose operations exceeded 4
hours. There were similar rates of infections associated
with bypass grafts and valve procedures (Table VI).
There were no significant differences among the 13
centers (data not shown).
Gram-positive bacteria caused 143 (74%) of 191
wound infections, and gram-negative bacteria caused
the other 48 (25%) infections (Table VII). Of these, 83
of the gram-positive isolates were in teicoplanin recip-
ients, and 60 were in those receiving cefazolin.
Pathogens associated with the 7 cases of sternal
osteomyelitis included coagulase-negative staphylo-
cocci (n = 5), Proprionibacterium species (n = 1), and
Escherichia coli (n = 1).
One hundred twenty-seven (75%) respiratory isolates
were gram-negative bacteria, 38 (22%) were gram-pos-
itive bacteria, and 6 (3%) were yeast. Approximately
three quarters of the gram-negative respiratory isolates
and two thirds of the gram-positive isolates originated
from the teicoplanin arm of the study. In the urinary
tract there were 14 gram-positive and 113 gram-nega-
tive isolates. Ninety-nine of the 113 gram-negative iso-
lates were in the teicoplanin group.
Overall, more infections were caused by coagulase-
negative staphylococci and gram-negative rods in the
teicoplanin group. Enterococcal infections were more
common in the cefazolin arm. Gram-positive isolates
Table IV. Differences between teicoplanin and cefazolin in rates of infection outside the thoracic surgical site
Cumulative 
number of 
Teicoplanin Cefazolin P value Teicoplanin Cefazolin P value Teicoplanin Cefazolin P value patients
Wound infections: donor site
Superficial 29 29 NS 68 84 NS 86 97 NS 183
Deep 1 8 .043* 4 9 NS 4 13 .047* 17
Respiratory tract infections
Definite pneumonia 29 18 NS 29 20 NS 31 23 NS 54
Probable pneumonia 12 4 NS 13 4 NS 14 4 .35 18
Tracheobronchitis 63 41 .039 74 47 .017 82 54 .021 136
Other
Bacteremia 14 8 NS 15 11 NS 18 11 NS 29
Urinary tract infections 101 24 .001 114 27 .001 122 34 .001 156
NS, Not significant.
*Not significant because P value required for significance was established at .0412.
Hospital discharge 30 days postoperatively 6 months postoperatively
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were all susceptible to teicoplanin. Eight percent of the
gram-positive infections and 34% of the gram-negative
infections were resistant to cefazolin (Table VIII). All
teicoplanin wound infections were caused by gram-
positive bacteria, which were shown to be susceptible
in vitro to teicoplanin. A similar observation was made
with cefazolin in that all but 5 gram-positive isolates
from surgical infections were sensitive to cefazolin.
One hundred ninety-six gram-positive strains, includ-
ing 82 S aureus, 84 S epidermidis, and 30 other
Staphylococcus species (1 S hominis, 3 S capitis, 9 S
haemolyticus, 12 S simulans, and 5 S warneri), were
tested for the presence of the mec A gene by using a
PCR primer (Table IX).21 There were 5 mec A–positive
S aureus (6%) strains and 42 mec A–positive S epider-
midis (50%) strains. This resistance gene was not
observed in the other staphylococcal species. Three S
epidermidis strains harbored this gene, and they were
susceptible to oxacillin, as determined by standard phe-
notypic susceptibility testing. We were successful in
inducing resistance in vitro to oxacillin in all of these
strains.
Seventy (2.3%) people died during this study (Table
X). There was no difference between groups in mortal-
ity rates in general or mortality rates attributed to infec-
tion (0.9% for the teicoplanin arm and 0.82% for the
cefazolin arm). There was no difference in severe cir-
culatory disease postoperatively. Very few patients
were lost to follow-up (Table X).
Duration of hospitalization postoperatively, which
was 10 days in the teicoplanin group and 9.5 days in
the cefazolin group, was similar, as was the duration of
intensive care (Table XI). Three hundred twenty (21%)
members of the teicoplanin cohort were readmitted for
acute or convalescent care compared with 20% of the
cefazolin cohort. Deep thoracic infections exerted a
profound influence on the duration of hospitalization
(Table XII). Irrespective of prophylaxis groups, there
was a 20-day prolongation of hospital stay in the
infected patients.
A total of 157 adverse events in 106 patients were
attributed to the study drugs, mostly nausea and vomit-
ing. There was no difference between the 2 drug arms
(Table XIII).
Discussion
In this study cefazolin provided more effective pro-
phylaxis against superficial and deep surgical infec-
tions than teicoplanin. Notably, sternal osteomyelitis
was observed only in the teicoplanin group. Urinary
tract infection and tracheobronchitis were likewise sig-
nificantly more common in teicoplanin recipients.
Infection was not associated with increased mortality
in this group of patients. However, in both arms of the
study, deep thoracic infections dramatically prolonged
hospitalization by 20 days.
The 1.1% absolute difference in deep thoracic infec-
tions noted after 6 months of observation (ie, from
2.4% to 1.3% in the respective arms) is small. That
there was a significant difference between groups
reflects the statistical power of the study, which was the
largest of its kind yet reported, and the 6-month period
of observation, which allowed delayed surgical site
infections to become manifest.
In view of the fact that this study was performed in
13 centers over a vast geographic area, it reflects more
than a local idiosyncrasy of microbial flora. The nature
of the glycopeptide-cephalosporin comparison is com-
plex. Glycopeptides are more reliably active in vitro
against staphylococci harboring the mec A gene,
Table V. Risk factors associated with deep thoracic
infections at 30 days postoperatively
Teicoplanin (%) Cefazolin (%) P value
Sex
Male subjects 2.25 1.34 .1775
Female subjects 1.34 0.67
Diabetic status
Diabetes 4.88 2.67 <.0001
No diabetes 1.40 0.84
Age
≤65 y 1.84 0.95 .1755
>65 y 2.45 1.65
Body mass index
<27 units 1.82 1.13 .4742
>27 units 2.32 1.30
Operation duration
<4 h 1.12 0.55 .0001
>4 h 3.49 2.24
Preoperative stay
<5 d 1.72 1.06 .1099
≥5 d 2.87 1.55
Overall infection rate 2.07 1.21
Table VI. Total deep thoracic infections by 
procedure*
30 d
Teicoplanin Cefazolin Total
CABG 26/1240 (2.1%) 13/1227 (1.1%) 39
Valve 2/89 (1.1%) 3/198 (1.5%) 5
CABG plus valve 3/89 (3.5%) 2/84 (2.4%) 5
*Differences between antibotic groups and procedures are not significant.
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notably S epidermidis, and enterococci. Glycopeptides
are more narrow in spectrum and should therefore be
less of a disruption to the patient’s endogenous flora.
Because 50% of the S epidermidis strains isolated in
our study were resistant to methicillin and harbored the
mec A gene, the greater number of gram-positive sur-
gical infections in the teicoplanin group was unexpect-
ed. Inexplicably, although 100% of the gram-positive
pathogens isolated in our patients remained susceptible
to teicoplanin in vitro, gram-positive bacteria were
more common in the teicoplanin group than the cefa-
zolin group in thoracic wound infections, both deep
and superficial, as well as in respiratory tract infec-
tions. Of particular concern was the high proportion
(6/7) of gram-positive infections among the patients
with sternal osteomyelitis, all of which occurred in
teicoplanin recipients. In leg incisions and in the uri-
nary tract, there were more gram-positive infections in
the cefazolin group than in the teicoplanin group.
On the basis of in vitro antimicrobial activity and
pharmacokinetic data, teicoplanin appeared to be a
very promising prophylactic agent for cardiac opera-
tions. Previous studies had shown that the ratio of
teicoplanin concentrations (ie, cardiac tissue/serum)
varied between 1.1 and 10, which was higher than
those obtained previously with fusidic acid (0.33),
cloxacillin (0.73), cefamandole (0.35), cefazolin
(0.23), and vancomycin (0.2-0.4).26,32
Moreover, 24 hours after the preoperative infusion
of a 12 mg/kg dose, which was less than the 15 mg/kg
Table VII. Cause of infections
Gram-positive bacteria (n, teicoplanin/cefazolin)
Staphylococci
Sites Total Coagulase + Coagulase – Enterococci Other
Deep thoracic wound infections 26/19 3/8 22/6 0/1 1/4
Superficial thoracic wound infections 38/16 11/3 25/11 1/2 1/0
Donor sites (deep and superficial) 19/25 8/15 9/3 1/3 1/4
Respiratory tract infections 25/13 17/7 5/2 0/0 3/4
Urinary tract infections 1/13 0/0 0/4 0/8 1/1
Bacteremia 6/7 0/5 6/1 — 0/1
Total isolates 115/93 39/38 67/27 2/14 7/14
Table VIII. Susceptibility of bacterial pathogens isolated from infected patients
Gram status Teicoplanin Cefazolin
Gram positive (n = 205) Susceptible* 205 (100%) 188 (91.7%)
Resistant† 0 17 (8.3%)
Gram negative (n = 195) Susceptible ND 128 (66%)
Resistant ND 67 (34%)
ND, Not done; teicoplanin lacks gram-negative activity.
*Susceptible strains: teicoplanin MIC, 8 µg/mL; cefazolin MIC, 8 µg/mL.
†Resistant strains: teicoplanin MIC, 32 µg/mL; cefazolin MIC, 32 µg/mL.
NCCLS. Performance Standards for Antimicrobial Susceptibility testing; Fifth International Supplement. NCCLS Document M100-S5. Villanova (PA): NCCLS;
1994. Vol. 14, No. 16.
Table IX. Presence or absence of mec A gene in 196 staphylococcal species
Strains No. mec A gene present mec A gene absent
S aureus 82 5 77
S epidermidis 84 42 (3)* 42
Staphylococcus species 30 0 30
*Three strains of S epidermidis were susceptible to oxacillin, as determined by using Kirby-Bauer disk susceptibility testing, and had an mec A gene. We were suc-
cessful in inducing resistance in vitro to oxacillin in these 3 strains.
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used in this study, patients undergoing cardiac surgery
had serum teicoplanin levels above the minimal
inhibitory concentrations (MICs) for 90% of gram-
positive pathogens. Mean concentrations detected in
heart tissue were 10 to 20 times higher than the MICs
for 90% of methicillin-susceptible and methicillin-
resistant S aureus and S epidermidis, Enterococcus
faecalis, and Corynebacterium jeikeium. This was in
contrast to the concentration of vancomycin in heart
tissue, which approximates the MIC for these organ-
isms. Moreover, although maximum levels of
cefamandole, cloxacillin, and flucloxacillin were 4 to
8 times higher than the MICs of these antibiotics
against methicillin-susceptible bacteria, they were
lower than the MICs for methicillin-resistant bacteria.
The same applies for cefazolin.32
Interestingly, all the escape bacteremia (ie, bac-
teremia caused by microorganisms susceptible to
antimicrobials) associated with teicoplanin prophylax-
is was caused by S epidermidis. In contrast, most of the
cases of gram-positive pneumonia and tracheobronchi-
tis were caused by S aureus, against which teicoplanin
has excellent in vitro activity.
Why was teicoplanin less effective than cefazolin
against sternal wound infections? The kinetics of
teicoplanin may have played against the drug.
Teicoplanin is highly protein bound (ie, approximately
90%).33,34 Levels of free drug are relatively low, and
Table X. Morbidity-mortality*
End point Teicoplanin (n = 1527) Cefazolin (n = 1520) P value
Myocardial infarction 40 (2.6) 34 (2.2) NS
Stroke 19 (1.2) 20 (1.3) NS
Pulmonary embolism 8 (0.5) 6 (0.4) NS
Death with ongoing infection 14 (0.9) 12 (0.8) NS
Death (all) 35 (2.3) 35 (2.3) NS
Lost to follow-up 10 (0.7) 13 (0.8) NS
All values are given as number (%).
*No differences were significant.
Table XI. Patient disposition postoperatively
Teicoplanin Cefazolin
Duration of postoperative hospitalization, d (mean ± SD) 10.0 ± 7.9 9.5 ± 6.7
Time in ICU, d (mean ± SD) 3.21 ± 3.81 3.02 ± 3.32
Need for ICU readmission, n (%) 52 (3.4) 49 (3.3)
Hospital readmission, n (%) 320 (21.1) 297 (19.7)
Nonconvalescent, n (%) 246 (16.2) 243 (16.1)
Convalescent, n (%) 95 (6.3) 69 (4.6)
Need for reoperation during hospitalization, n (%) 52 (3.4) 42 (2.8)
Gram-negative bacteria (n, teicoplanin/cefazolin)
Total Enterobacteriaceae Nonfermenters Other Yeast (n, teicoplanin/cefazolin)
4/3 3/3 1/0 — —
7/2 7/1 0/1 — —
10/22 8/20 2/2 — 0/1
96/31 31/9 7/3 58/19 3/3
99/14 95/13 3/1 1/0 3/0
9/1 9/1 — — —
225/73 153/47 13/7 59/19 6/4
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activity is correspondingly reduced.35,36 Although lev-
els of teicoplanin are high in cardiac tissue,26 they are
low in presternal subcutaneous fat.37 Teicoplanin pene-
trates sternal bone poorly.38 We attempted to overcome
these negative features by using a high dose of
teicoplanin (ie, 15 mg/kg).
Furthermore, although glycopeptides, including
teicoplanin, exhibit good in vitro activity against gram-
positive bacteria, as determined by MICs, these drugs
are only slowly bactericidal compared with β-lac-
tams.35 This may be an important detriment to activity
in prophylaxis. Also, when compared with van-
comycin, teicoplanin has only modest activity against S
epidermidis.39-42
Glycopeptides provide no activity against facultative
gram-negative rods, which may cause operative and
nonoperative site infections. A priori we were con-
cerned about the potential for gram-negative infections
in the teicoplanin group. This concern was realized in
urinary and respiratory tract infections and in bac-
teremia. Of particular interest is the fact that there were
more gram-negative deep and superficial donor site
infections in the cefazolin group than in the teicoplanin
arm and that these infections were due, for the most
part, to cefazolin-susceptible enterobacteriaceae. For
gram-negative infections at other sites, cefazolin pro-
vided effective prophylaxis, despite a 34% resistance
rate of gram-negative pathogens to cefazolin in this
study. With such high levels of resistance, one would
have expected more gram-negative infections in the
cefazolin group than those observed. The conventional
concept of MIC may not be entirely applicable to pro-
phylaxis. Other factors, such as rate of kill and inocu-
lum effect, may also explain some of the apparent dis-
crepancies observed here.
Previous studies have suggested that male sex, old
age, obesity, and prolonged preoperative stay were
determinant factors increasing the likelihood of infec-
tious complications. In our present clinical trial, dia-
betes mellitus and the duration of operation appear as
the only significant risk factors for the development of
infections.
Adverse events in both groups were relatively
uncommon and generally inconsequential. Of note,
hypotension was not a problem with teicoplanin, occur-
ring with similar frequency as with cefazolin. This sup-
ports the data of Sahai and associates,28 differentiating
teicoplanin from vancomycin. Whereas vancomycin
induces histamine release, teicoplanin does not.
This study was done in centers with a low prevalence
of MRSA. Vancomycin would be indicated if MRSA
were the predominant strain of S aureus. One histori-
cally controlled study suggested equivalence of van-
comycin and teicoplanin. A rigorous randomized con-
trolled trial between these 2 drugs would be of great
interest. Until that time, no definite statement can be
made about the comparative efficacy of vancomycin
and teicoplanin.
In conclusion, cefazolin provided more effective pro-
phylaxis than teicoplanin in preventing postoperative
infections after cardiac operations.
We thank Francis Martineau for expert performance of 
mec A gene detection.
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